These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 18820683

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cancer exploiting complement: a clue or an exception?
    Loveland BE, Cebon J.
    Nat Immunol; 2008 Nov; 9(11):1205-6. PubMed ID: 18936777
    [No Abstract] [Full Text] [Related]

  • 3. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche.
    Vadrevu SK, Chintala NK, Sharma SK, Sharma P, Cleveland C, Riediger L, Manne S, Fairlie DP, Gorczyca W, Almanza O, Karbowniczek M, Markiewski MM.
    Cancer Res; 2014 Jul 01; 74(13):3454-65. PubMed ID: 24786787
    [Abstract] [Full Text] [Related]

  • 4. Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness.
    Nitta H, Murakami Y, Wada Y, Eto M, Baba H, Imamura T.
    Oncol Rep; 2014 Oct 01; 32(4):1715-9. PubMed ID: 25050844
    [Abstract] [Full Text] [Related]

  • 5. Complement C5a promotes antigen cross-presentation by Peyer's patch monocyte-derived dendritic cells and drives a protective CD8+ T cell response.
    Kim SH, Cho BH, Kim KS, Jang YS.
    Cell Rep; 2021 Apr 13; 35(2):108995. PubMed ID: 33852847
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation.
    Raedler H, Yang M, Lalli PN, Medof ME, Heeger PS.
    Am J Transplant; 2009 Aug 13; 9(8):1784-95. PubMed ID: 19563342
    [Abstract] [Full Text] [Related]

  • 9. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.
    Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM, Pio R.
    J Immunol; 2012 Nov 01; 189(9):4674-83. PubMed ID: 23028051
    [Abstract] [Full Text] [Related]

  • 10. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.
    Carvelli J, Demaria O, Vély F, Batista L, Chouaki Benmansour N, Fares J, Carpentier S, Thibult ML, Morel A, Remark R, André P, Represa A, Piperoglou C, Explore COVID-19 IPH group, Explore COVID-19 Marseille Immunopole group, Cordier PY, Le Dault E, Guervilly C, Simeone P, Gainnier M, Morel Y, Ebbo M, Schleinitz N, Vivier E.
    Nature; 2020 Dec 01; 588(7836):146-150. PubMed ID: 32726800
    [Abstract] [Full Text] [Related]

  • 11. C5a and pain development: An old molecule, a new target.
    Quadros AU, Cunha TM.
    Pharmacol Res; 2016 Oct 01; 112():58-67. PubMed ID: 26855316
    [Abstract] [Full Text] [Related]

  • 12. Food intake regulation by central complement system.
    Ohinata K, Yoshikawa M.
    Adv Exp Med Biol; 2008 Oct 01; 632():35-46. PubMed ID: 19025112
    [Abstract] [Full Text] [Related]

  • 13. Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model.
    Atkinson SM, Nansen A, Usher PA, Sondergaard BC, Mackay CR, Friedrichsen B, Chang CC, Tang R, Skov S, Haase C, Hornum L.
    Autoimmunity; 2015 Oct 01; 48(7):460-70. PubMed ID: 25915570
    [Abstract] [Full Text] [Related]

  • 14. Complement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration.
    Piao C, Cai L, Qiu S, Jia L, Song W, Du J.
    J Biol Chem; 2015 Apr 24; 290(17):10667-76. PubMed ID: 25739439
    [Abstract] [Full Text] [Related]

  • 15. Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses.
    Kim AH, Dimitriou ID, Holland MC, Mastellos D, Mueller YM, Altman JD, Lambris JD, Katsikis PD.
    J Immunol; 2004 Aug 15; 173(4):2524-9. PubMed ID: 15294968
    [Abstract] [Full Text] [Related]

  • 16. Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses.
    Rudilla F, Fayolle C, Casares N, Durantez M, Arribillaga L, Lozano T, Villanueva L, Pio R, Sarobe P, Leclerc C, Prieto J, Lasarte JJ.
    Vaccine; 2012 Apr 16; 30(18):2848-58. PubMed ID: 22387222
    [Abstract] [Full Text] [Related]

  • 17. C5a/C5aR pathway is essential for the pathogenesis of murine viral fulminant hepatitis by way of potentiating Fgl2/fibroleukin expression.
    Xu GL, Chen J, Yang F, Li GQ, Zheng LX, Wu YZ.
    Hepatology; 2014 Jul 16; 60(1):114-24. PubMed ID: 24604562
    [Abstract] [Full Text] [Related]

  • 18. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
    Hosoi A, Matsushita H, Shimizu K, Fujii S, Ueha S, Abe J, Kurachi M, Maekawa R, Matsushima K, Kakimi K.
    Int J Cancer; 2014 Apr 15; 134(8):1810-22. PubMed ID: 24150772
    [Abstract] [Full Text] [Related]

  • 19. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice.
    Kumar V, Ali SR, Konrad S, Zwirner J, Verbeek JS, Schmidt RE, Gessner JE.
    J Clin Invest; 2006 Feb 15; 116(2):512-20. PubMed ID: 16453025
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.